UNSPSC 51313105: Hydroxyzine embonate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H27ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30S50YM8OG, chemically known as ethanol, 2-(2-(4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)- but generally known as hydroxyzine, which bears US NIH Compound Identifier 3658. European Medicines Agency schedules Hydroxyzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08088MIG.

UNSPSC 51313105 Hydroxyzine embonate, a Commodity code, nominally identifies a specific pharmaceutical compound, yet recent state and local opportunities solicited under this code do not consistently reflect purchases of hydroxyzine embonate itself. Instead, issuing bodies are procuring naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs through cooperative purchasing frameworks and individual county health initiatives. The work encompasses supply agreements for pharmaceutical products distributed through authorized wholesalers to state agencies, county health departments, and participating local government facilities, with vendors required to meet cGMP and Drug Supply Chain Security Act compliance, maintain relationships with specified wholesale partners, and deliver products on fixed-fee or negotiated net-pricing bases with quarterly or scheduled deliveries.

Recent activity spans Florida, Minnesota, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; pricing evaluation weighted 75 percent on competitiveness. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional PBM and wholesaler arrangements, functioning as preliminary market intelligence for future formal procurement rather than an immediate award vehicle.